Header Logo

Connection

Afaaf Liberty to Anti-HIV Agents

This is a "connection" page, showing publications Afaaf Liberty has written about Anti-HIV Agents.
Connection Strength

1,203
  1. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
    View in: PubMed
    Score: 0,128
  2. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
    View in: PubMed
    Score: 0,121
  3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
    View in: PubMed
    Score: 0,108
  4. Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence. BMC Public Health. 2022 07 08; 22(1):1312.
    View in: PubMed
    Score: 0,107
  5. Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):381-389.
    View in: PubMed
    Score: 0,091
  6. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
    View in: PubMed
    Score: 0,087
  7. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
    View in: PubMed
    Score: 0,087
  8. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019 01 24; 10(1):412.
    View in: PubMed
    Score: 0,084
  9. Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study. Pediatr Infect Dis J. 2018 06; 37(6):e149-e156.
    View in: PubMed
    Score: 0,081
  10. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
    View in: PubMed
    Score: 0,080
  11. Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late? J Int AIDS Soc. 2014; 17:18914.
    View in: PubMed
    Score: 0,061
  12. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 09; 382(9904):1555-63.
    View in: PubMed
    Score: 0,059
  13. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25; 487(7408):482-5.
    View in: PubMed
    Score: 0,054
  14. Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
    View in: PubMed
    Score: 0,032
  15. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
    View in: PubMed
    Score: 0,023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.